IceCure Medical Stock Forecast

ICCM's stock price has decreased by -77.02% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts that cover IceCure Medical stock have a consensus rating of "Strong Buy" and an average price target of $1.75, which forecasts a 661.53% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $2.50.

Price Target: $1.75 (+661.53%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1.00	$1.75	$2.50	$2.50
Change	+335.16%	+661.53%	+987.90%	+987.90%

Analyst Ratings

The average analyst rating for IceCure Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	1	1	1	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anthony Vendetti Maxim Group	Maxim Group	Strong Buy Maintains $3 → $1	Strong Buy	Maintains	$3 → $1	+335.16%	May 14, 2026
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $2 → $2.5	Strong Buy	Maintains	$2 → $2.5	+987.90%	Oct 7, 2025
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $2.5 → $2	Strong Buy	Maintains	$2.5 → $2	+770.32%	Aug 15, 2025
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $2.5	Strong Buy	Reiterates	$2.5	+987.90%	May 29, 2025
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $2.5	Strong Buy	Reiterates	$2.5	+987.90%	Mar 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

8.09M

from 3.38M

139.51%

from 3.38M

Revenue Next Year

14.22M

from 8.09M

75.66%

from 8.09M

EPS This Year

-0.19

from -0.24

EPS Next Year

-0.15

from -0.19

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	4.14M	3.09M	3.23M	3.29M	3.38M	8.09M	14.22M
Revenue Growth	6.98%	-25.45%	4.67%	1.92%	2.67%	139.51%	75.66%
EPS	-0.35	-0.46	-0.32	-0.30	-0.24	-0.19	-0.15
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	11.3M	21.3M
Avg	8.1M	14.2M
Low	5.0M	7.5M

Revenue Growth

Revenue Growth	2026	2027
High	235.2%	162.8%
Avg	139.5%	75.7%
Low	47.4%	-7.7%

EPS Forecast

EPS	2026	2027
High	-0.13	-0.08
Avg	-0.19	-0.15
Low	-0.25	-0.22

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.